Cardiff Oncology Inc.
CRDF | NASDAQ
$1.35
-$0.02 (-1.46%)
Sep 22, 2026, 2:17 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 593K | 683K | 488K | 386K | 359K | 366K |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 593K | 683K | 488K | 386K | 359K | 366K |
Operating Income | -48.96M | -48.65M | -45.41M | -39.9M | -28.86M | -19.09M |
Interest Income | 3.1M | 3.26M | 4.07M | 1.58M | 264K | 90K |
Pretax Income | -45.85M | -45.43M | -41.44M | -38.7M | -28.29M | -19.31M |
Net Income | -45.85M | -45.43M | -41.44M | -38.7M | -28.29M | -19.31M |
Selling & General & Admin | 14.22M | 12.48M | 13.04M | 13.18M | 11.84M | 8.22M |
Research & Development | 35.33M | 36.85M | 32.86M | 27.11M | 17.38M | 11.24M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 49.55M | 49.33M | 45.9M | 40.29M | 29.21M | 19.45M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 2K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 49.55M | 49.33M | 45.9M | 40.29M | 29.21M | 19.45M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 66.84M | 47.65M | 44.68M | 43.6M | 39.03M | 20.88M |
Shares Outstanding (Diluted) | 66.84M | 47.65M | 44.68M | 43.6M | 39.03M | 20.88M |
EPS (Basic) | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 |
EPS (Diluted) | -0.69 | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 |
EBITDA | -44.95M | -45.03M | -41.04M | -38.47M | -27.84M | -18.84M |
EBIT | -45.85M | -45.43M | -41.44M | -38.7M | -28.29M | -19.31M |
Depreciation & Amortization | 904K | 404K | 398K | 236K | 451K | 466K |
Add to Watchlist
Select watchlists to add or remove CRDF